JADENU

This brand name is authorized in United States. It is also authorized in Australia, Canada, Hong Kong SAR China, Japan, Singapore, South Africa, Tunisia.

Active ingredients

The drug JADENU contains one active pharmaceutical ingredient (API):

1	Deferasirox UNII V8G4MOF2V9 - DEFERASIROX
	Deferasirox is an orally active chelator that is highly selective for iron (III). It is a tridentate ligand that binds iron with high affinity in a 2:1 ratio. Deferasirox promotes excretion of iron, primarily in the faeces.
	Read more about Deferasirox

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
JADENU Film-coated tablet / Granules	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
V03AC03	Deferasirox	V Various → V03 All other therapeutic products → V03A All other therapeutic products → V03AC Iron chelating agents
Discover more medicines within V03AC03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	11496C, 11499F, 11500G, 11510T, 11511W, 11519G, 11533B, 11534C, 11535D, 11536E, 11545P, 11546Q, 11547R, 11548T, 11555E, 11556F, 11557G, 11558H
CA	Health Products and Food Branch	02452219, 02452227, 02452235
HK	Department of Health Drug Office	64785, 64786, 64787
JP	医薬品医療機器総合機構	3929008D1022, 3929008D2029
SG	Health Sciences Authority	15213P, 15214P, 15215P
TN	Direction de la Pharmacie et du Médicament	10283421H, 10283422H, 10283423H
US	FDA, National Drug Code	0078-0654, 0078-0655, 0078-0656, 0078-0713, 0078-0720, 0078-0727
ZA	Health Products Regulatory Authority	50/27/0768, 50/27/0769, 50/27/0770